Crinetics Pharmaceuticals
CRNX
171 hedge funds and large institutions have $2.04B invested in Crinetics Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 51 funds opening new positions, 81 increasing their positions, 29 reducing their positions, and 19 closing their positions.
179% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 29
168% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 19
117% more funds holding in top 10
Funds holding in top 10: 6 → 13 (+7)
109% more capital invested
Capital invested by funds: $974M → $2.04B (+$1.06B)
22% more funds holding
Funds holding: 140 → 171 (+31)
3.54% more ownership
Funds ownership: 100.05% → 103.59% (+3.5%)
6% less call options, than puts
Call options by funds: $31.7M | Put options by funds: $33.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$87.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23.7M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$22.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.8M |
| 5 |
Jennison Associates
New York
|
+$20M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$21.7M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$21.2M |
| 3 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$14.4M |
| 4 |
PA
Perceptive Advisors
New York
|
-$14.1M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$11.7M |
CRNX Hedge Fund Activity: Q3 2023 in Review
171 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q3 2023, worth a combined $2.04B — up 109% from $974M a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new CRNX positions and 19 closed out — a net gain of 32 holders — while 81 added to existing stakes and 29 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $87.1M. The largest seller was OrbiMed, cutting an estimated $21.7M.
- 171 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q3 2023, up from 140 in Q2 2023.
- Funds reported $2.04B of Crinetics Pharmaceuticals stock for Q3 2023, up 109% quarter-over-quarter.
- 51 funds opened new Crinetics Pharmaceuticals positions in Q3 2023 and 19 closed out, a net change of +32 holders.
- The largest Crinetics Pharmaceuticals buyer in Q3 2023 was Point72 Asset Management, an estimated $87.1M added.
- The largest Crinetics Pharmaceuticals seller in Q3 2023 was OrbiMed, an estimated $21.7M sold.
Based on aggregated 13F filings for Q3 2023.